Probiotic Therapy of Gastrointestinal Symptoms During COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled, Remote Study

Overview

Journal Nutrients

Date 2024 Nov 27

PMID 39599756

Authors

Angela Horvath

Rosa Haller

Nicole Feldbacher

Hansjorg Habisch

Kristina Zukauskaite

Tobias Madl

Vanessa Stadlbauer

Affiliations

Soon will be listed here.

Abstract

Background: The novel coronavirus (SARS-CoV-2) led to gastrointestinal manifestations in up to 50% of cases, with diarrhea being common, and probiotics have been suggested as a potential treatment.

Aim: This study aimed to assess changes in the microbiome and the effects of a multispecies probiotic in patients with COVID-19 in home quarantine through a fully remote telemedical approach.

Methods: Thirty patients were randomized to receive either the Ecologic AAD probiotic (Winclove Probiotics, Amsterdam, The Netherlands), on the market as OMNi-BiOTiC 10 (Allergosan, Austria), or a placebo for 30 days in a 2:1 ratio. Respiratory and gastrointestinal symptoms were monitored in 2-10-day intervals via online surveys, and five stool samples were collected during the 30-day study period for microbiome and metabolomics analyses. Twenty-four healthy volunteers served as controls.

Results: Of the 30 patients, 26 completed this study (10 placebo, 16 probiotic). Patients reported respiratory symptoms and a diminished gastrointestinal quality of life, both of which improved significantly during the study period, irrespective of the intervention. Compared to controls, infected patients showed significant alterations in the fecal microbiome ( = 0.002), including an increase in Bacteroidetes and decreases in Christensenellaceae, Ruminococcaceae, and Gammaproteobacteria, along with metabolomic changes. Probiotic treatment significantly modulated the patients' microbiome beta diversity ( = 0.001) and introduced the W54 strain. Symptoms, COVID-19-related taxa, and the fecal metabolome were not affected by the intervention.

Conclusions: Patients with mild COVID-19 disease in home quarantine exhibited respiratory symptoms, a reduced gastrointestinal quality of life, and changes in the fecal microbiome and metabolome.

References

Effenberger M, Grabherr F, Mayr L, Schwaerzler J, Nairz M, Seifert M . Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut. 2020; 69(8):1543-1544. PMC: 7211078. DOI: 10.1136/gutjnl-2020-321388. View

Caporaso J, Lauber C, Walters W, Berg-Lyons D, Huntley J, Fierer N . Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J. 2012; 6(8):1621-4. PMC: 3400413. DOI: 10.1038/ismej.2012.8. View

Slykerman R, Li E . A randomized trial of probiotic supplementation in nurses to reduce stress and viral illness. Sci Rep. 2022; 12(1):14742. PMC: 9427766. DOI: 10.1038/s41598-022-19104-9. View

Hindson J . COVID-19: faecal-oral transmission?. Nat Rev Gastroenterol Hepatol. 2020; 17(5):259. PMC: 7095230. DOI: 10.1038/s41575-020-0295-7. View

Watson N, Mull K, Heffner J, McClure J, Bricker J . Participant Recruitment and Retention in Remote eHealth Intervention Trials: Methods and Lessons Learned From a Large Randomized Controlled Trial of Two Web-Based Smoking Interventions. J Med Internet Res. 2018; 20(8):e10351. PMC: 6128955. DOI: 10.2196/10351. View

Tariq R, Saha S, Furqan F, Hassett L, Pardi D, Khanna S . Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Meta-analysis. Mayo Clin Proc. 2020; 95(8):1632-1648. PMC: 7284248. DOI: 10.1016/j.mayocp.2020.06.003. View

Zhang W, Du R, Li B, Zheng X, Yang X, Hu B . Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020; 9(1):386-389. PMC: 7048229. DOI: 10.1080/22221751.2020.1729071. View

Kumpitsch C, Fischmeister F, Mahnert A, Lackner S, Wilding M, Sturm C . Reduced B12 uptake and increased gastrointestinal formate are associated with archaeome-mediated breath methane emission in humans. Microbiome. 2021; 9(1):193. PMC: 8464155. DOI: 10.1186/s40168-021-01130-w. View

Gutierrez-Castrellon P, Gandara-Marti T, Abreu Y Abreu A, Nieto-Rufino C, Lopez-Orduna E, Jimenez-Escobar I . Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes. 2022; 14(1):2018899. PMC: 8757475. DOI: 10.1080/19490976.2021.2018899. View

10.

Dieterle F, Ross A, Schlotterbeck G, Senn H . Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem. 2006; 78(13):4281-90. DOI: 10.1021/ac051632c. View

11.

Luise D, Correa F, Bosi P, Trevisi P . A Review of the Effect of Formic Acid and Its Salts on the Gastrointestinal Microbiota and Performance of Pigs. Animals (Basel). 2020; 10(5). PMC: 7278376. DOI: 10.3390/ani10050887. View

12.

Yeo C, Kaushal S, Yeo D . Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible?. Lancet Gastroenterol Hepatol. 2020; 5(4):335-337. PMC: 7130008. DOI: 10.1016/S2468-1253(20)30048-0. View

13.

Xie J, Wang Y, Zhong Q, Bai S, Zhou C, Tian T . Associations Between Disordered Microbial Metabolites and Changes of Neurotransmitters in Depressed Mice. Front Cell Infect Microbiol. 2022; 12:906303. PMC: 9163491. DOI: 10.3389/fcimb.2022.906303. View

14.

Wei X, Wang X, Niu Y, Ye L, Peng W, Wang Z . Diarrhea Is Associated With Prolonged Symptoms and Viral Carriage in Corona Virus Disease 2019. Clin Gastroenterol Hepatol. 2020; 18(8):1753-1759.e2. PMC: 7165091. DOI: 10.1016/j.cgh.2020.04.030. View

15.

Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H . The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 7(1):11. PMC: 7068984. DOI: 10.1186/s40779-020-00240-0. View

16.

Guo M, Tao W, Flavell R, Zhu S . Potential intestinal infection and faecal-oral transmission of SARS-CoV-2. Nat Rev Gastroenterol Hepatol. 2021; 18(4):269-283. PMC: 7883337. DOI: 10.1038/s41575-021-00416-6. View

17.

van Wietmarschen H, Busch M, van Oostveen A, Pot G, Jong M . Probiotics use for antibiotic-associated diarrhea: a pragmatic participatory evaluation in nursing homes. BMC Gastroenterol. 2020; 20(1):151. PMC: 7222499. DOI: 10.1186/s12876-020-01297-w. View

18.

Donati Zeppa S, Agostini D, Piccoli G, Stocchi V, Sestili P . Gut Microbiota Status in COVID-19: An Unrecognized Player?. Front Cell Infect Microbiol. 2020; 10:576551. PMC: 7725702. DOI: 10.3389/fcimb.2020.576551. View

19.

Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S . [Management of COVID-19: the Zhejiang experience]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020; 49(2):147-157. PMC: 8800711. DOI: 10.3785/j.issn.1008-9292.2020.02.02. View

20.

Hussain I, Cher G, Abid M, Abid M . Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential. Front Immunol. 2021; 12:765965. PMC: 8551858. DOI: 10.3389/fimmu.2021.765965. View